BR0014063A - Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas - Google Patents

Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas

Info

Publication number
BR0014063A
BR0014063A BR0014063-5A BR0014063A BR0014063A BR 0014063 A BR0014063 A BR 0014063A BR 0014063 A BR0014063 A BR 0014063A BR 0014063 A BR0014063 A BR 0014063A
Authority
BR
Brazil
Prior art keywords
formulations
estramustine phosphate
pharmacological properties
parenteral use
improved pharmacological
Prior art date
Application number
BR0014063-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0014063A publication Critical patent/BR0014063A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0014063-5A 1999-09-16 2000-08-03 Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas BR0014063A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
BR0014063A true BR0014063A (pt) 2004-06-29

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014063-5A BR0014063A (pt) 1999-09-16 2000-08-03 Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas

Country Status (20)

Country Link
EP (1) EP1212040A1 (ko)
JP (1) JP2003509355A (ko)
KR (1) KR20020059405A (ko)
CN (1) CN1177583C (ko)
AU (1) AU777763B2 (ko)
BR (1) BR0014063A (ko)
CA (1) CA2385063A1 (ko)
CZ (1) CZ2002943A3 (ko)
EA (1) EA005308B1 (ko)
GB (1) GB9921954D0 (ko)
HK (1) HK1047227A1 (ko)
HU (1) HUP0202621A2 (ko)
IL (1) IL148409A0 (ko)
MX (1) MXPA02002859A (ko)
NO (1) NO20021306L (ko)
NZ (1) NZ517631A (ko)
PL (1) PL353954A1 (ko)
SK (1) SK3452002A3 (ko)
WO (1) WO2001019338A1 (ko)
ZA (1) ZA200201743B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2620023B1 (en) 2010-09-21 2018-02-28 Telefonaktiebolaget LM Ericsson (publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
AU777763B2 (en) 2004-10-28
CN1374858A (zh) 2002-10-16
CN1177583C (zh) 2004-12-01
HUP0202621A2 (hu) 2002-12-28
WO2001019338A1 (en) 2001-03-22
EA200200369A1 (ru) 2002-08-29
EP1212040A1 (en) 2002-06-12
AU6836300A (en) 2001-04-17
SK3452002A3 (en) 2002-08-06
ZA200201743B (en) 2003-05-28
CZ2002943A3 (cs) 2002-08-14
JP2003509355A (ja) 2003-03-11
NO20021306D0 (no) 2002-03-15
KR20020059405A (ko) 2002-07-12
GB9921954D0 (en) 1999-11-17
IL148409A0 (en) 2002-09-12
CA2385063A1 (en) 2001-03-22
MXPA02002859A (es) 2003-07-21
EA005308B1 (ru) 2004-12-30
NO20021306L (no) 2002-04-24
HK1047227A1 (zh) 2003-02-14
PL353954A1 (en) 2003-12-15
NZ517631A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
BR9911046A (pt) Uso de antidepressivos tricìclicos para analgesia local
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
TR200002299T2 (tr) Epotilon kompozisyonları.
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
BR0014071A (pt) Formulações para uso parenteral de fosfato de estramustina e aminoácidos
TR200003108T2 (tr) İlaç kompozisyonları
IL140930A0 (en) Compounds and compositions for delivering active agents
IT1311923B1 (it) Composti farmaceutici.
NZ501235A (en) Topical compositions containing emulsion of a discontinuous phase which is an eutectic mixture of two pharmaceutical agents and a continuous phase
RS84904A (en) Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
ES2167609T3 (es) Formulaciones de quinolona inyectables.
BR9912827A (pt) Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
DE60137960D1 (de) Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
BR0008468A (pt) Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
BR0014062A (pt) Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas
ATE378070T1 (de) Zusammensetzung mit fulvestrant
BR0014063A (pt) Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas
GT200100063A (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
BR0016177A (pt) Espuma em fios ocos e preparação da mesma
BR9714047A (pt) Derivados de ácido carboxìlico, uso dos mesmos, combinação destes com um ou mais compostos ativos, preparação de drogas para a administração oral e parenteral, e, antagonista de receptor de endotelina
NO20020631L (no) Formuleringer for parenteral bruk av estramustinfosfat og albumin
PT1058544E (pt) Inibicao da actividade do tnf
BR0112035A (pt) peptìdeos antimicrobianos de novispirin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.